Revenue Insights: Takeda Pharmaceutical Company Limited and ADMA Biologics, Inc. Performance Compared

Biopharma Revenue Growth: Takeda vs. ADMA

__timestampADMA Biologics, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 201459155451777824000000
Thursday, January 1, 201571776331807378000000
Friday, January 1, 2016106610371732051000000
Sunday, January 1, 2017227605601770531000000
Monday, January 1, 2018169852902097224000000
Tuesday, January 1, 2019293490833291188000000
Wednesday, January 1, 2020422197833197812000000
Friday, January 1, 2021809426253569006000000
Saturday, January 1, 20221540796924027478000000
Sunday, January 1, 20232582149994263762000000
Monday, January 1, 20244263762000000
Loading chart...

In pursuit of knowledge

Revenue Growth: A Tale of Two Biopharma Giants

In the dynamic world of biopharmaceuticals, revenue growth is a key indicator of success. Takeda Pharmaceutical Company Limited, a global leader, has shown a remarkable revenue increase of approximately 140% from 2014 to 2023. In contrast, ADMA Biologics, Inc., a smaller player, has experienced an impressive growth of over 4,200% in the same period, albeit from a much smaller base.

Takeda's Steady Ascent

Takeda's revenue journey reflects its strategic acquisitions and robust product pipeline, with revenues peaking at over $4 trillion in 2023. This steady growth underscores its dominance in the pharmaceutical industry.

ADMA's Meteoric Rise

ADMA Biologics, while starting with modest revenues, has shown exponential growth, reaching over $250 million by 2023. This surge highlights its successful niche focus and innovative therapies.

Missing Data for 2024

While Takeda's 2024 data is available, ADMA's is not, leaving room for speculation on its future trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025